Terms: = Prostate cancer AND NUP214, ENSG00000126883, 8021, MGC104525, D9S46E, RP11-544A12_7, N214, CAIN, P35658, CAN AND Diagnosis
4977 results:
1. [Construction of a model based on multipoint full-layer puncture biopsy for predicting pathological complete response after neoadjuvant therapy for locally advanced rectal cancer].
Jin Y; Zhai ZW; Sun LT; Xia PD; Hu H; Jiang CQ; Zhao BC; Qu H; Qian Q; Dai Y; Yao HW; Wang ZJ; Han JG
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):403-411. PubMed ID: 38644246
[No Abstract] [Full Text] [Related]
2. Patterns of Care for Medicare Beneficiaries With Metastatic prostate cancer.
Filson CP; Richards TB; Ekwueme DU; Howard DH
Urol Pract; 2024 May; 11(3):489-497. PubMed ID: 38640419
[TBL] [Abstract] [Full Text] [Related]
3. Racial and Ethnic Variation in Receipt and Intensity of Active Surveillance for Older Patients With Localized prostate cancer.
Basourakos SP; An A; Davuluri M; Pinheiro LC; Al Awamlh BAH; Borregales LD; Luan D; Tamimi RM; Hu JC; Kensler KH
Urol Pract; 2024 May; 11(3):538-546. PubMed ID: 38640417
[TBL] [Abstract] [Full Text] [Related]
4. [Application of 1470 nm semiconductor laser in the treatment of benign prostatic hyperplasia in ultra-aged patients].
Wu D; Yi XM; Wei HX; Zhang KX; Shi CJ; Shi XQ; Xu ZY; Fu D
Zhonghua Nan Ke Xue; 2023 Sep; 29(9):831-836. PubMed ID: 38639597
[TBL] [Abstract] [Full Text] [Related]
5. [A single center study：An analysis of the safety and validity of delaying repeated biopsy for patients with atypical small acinar proliferation].
Ji WT; Liu DC; Cui WL; Hu Y; Wang Y; Tan JF
Zhonghua Nan Ke Xue; 2023 May; 29(5):414-419. PubMed ID: 38602757
[TBL] [Abstract] [Full Text] [Related]
6. Is Unilateral Lymphadenectomy an Option in Selected Patients with prostate cancer?
Kassab BN; De Pablos-Rodríguez P; Ferrer ÁG; García AC; Fons AC; Aragón F; Ramón-Borja JC; Ramírez-Backhaus M
Arch Esp Urol; 2024 Mar; 77(2):129-134. PubMed ID: 38583004
[TBL] [Abstract] [Full Text] [Related]
7. The trend of dental check-up and prevalence of dental complications following the use of bone modifying agents in patients with metastatic breast and prostate cancer: analysis of data from the Korean National Health Insurance Service.
Lim AR; Park W; Moon SJ; Kim MS; Lee S
BMC Health Serv Res; 2024 Apr; 24(1):412. PubMed ID: 38566103
[TBL] [Abstract] [Full Text] [Related]
8. The treatment landscape of nonmetastatic castrate resistant prostate cancer: A contemporary perspective.
Yanada BA; Homewood D; Dias BH; Ogluszko C; Corcoran NM
Urol Oncol; 2024 Jun; 42(6):175.e9-175.e18. PubMed ID: 38555235
[TBL] [Abstract] [Full Text] [Related]
9. Safety of Docetaxel in a Patient with Metastatic Castration-Resistant prostate cancer After Kidney Transplantation: A Case Report.
Nagahisa C; Iizuka J; Kobari Y; Minoda R; Oki R; Unagami K; Yoshida K; Hirai T; Omoto K; Shimizu T; Ishida H; Takagi T
Transplant Proc; 2024 Apr; 56(3):729-733. PubMed ID: 38548511
[TBL] [Abstract] [Full Text] [Related]
10. DNA methylation markers for risk of metastasis in a cohort of men with localized prostate cancer.
Habeshian TS; Cannavale KL; Slezak JM; Shu YH; Chien GW; Chen X; Shi F; Siegmund KD; Van Den Eeden SK; Huang J; Chao CR
Epigenetics; 2024 Dec; 19(1):2308920. PubMed ID: 38525786
[TBL] [Abstract] [Full Text] [Related]
11. Adrenal-Permissive Germline HSD3B1 Allele and prostate cancer Outcomes.
McKay RR; Nelson TJ; Pagadala MS; Teerlink CC; Gao A; Bryant AK; Agiri FY; Guram K; Thompson RF; Pridgen KM; Seibert TM; Lee KM; Carter H; Lynch JA; Hauger RL; Rose BS
JAMA Netw Open; 2024 Mar; 7(3):e242976. PubMed ID: 38506808
[TBL] [Abstract] [Full Text] [Related]
12. Synchronous versus metachronous spinal metastasis: a comparative study of survival outcomes following neurosurgical treatment.
Banat M; Potthoff AL; Hamed M; Borger V; Scorzin JE; Lampmann T; Asoglu H; Khalafov L; Schmeel FC; Paech D; Radbruch A; Nitsch L; Weller J; Herrlinger U; Toma M; Gielen GH; Vatter H; Schneider M
J Cancer Res Clin Oncol; 2024 Mar; 150(3):136. PubMed ID: 38502313
[TBL] [Abstract] [Full Text] [Related]
13. Biomarker Inference and the Timing of Next-Generation Sequencing in a Multi-Institutional, Cross-cancer Clinicogenomic Data Set.
Kehl KL; Lavery JA; Brown S; Fuchs H; Riely G; Schrag D; Newcomb A; Nichols C; Micheel CM; Bedard PL; Sweeney SM; Fiandalo M; Panageas KS;
JCO Precis Oncol; 2024 Mar; 8():e2300489. PubMed ID: 38484212
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic factors among patients with pathological Grade Group 5 prostate cancer based on robot-associated radical prostatectomy specimens from a large Japanese cohort (MSUG94).
Sasaki T; Ebara S; Tatenuma T; Ikehata Y; Nakayama A; Kawase M; Toide M; Yoneda T; Sakaguchi K; Teishima J; Makiyama K; Kitamura H; Saito K; Koie T; Koga F; Urakami S; Inoue T
World J Urol; 2024 Mar; 42(1):152. PubMed ID: 38483586
[TBL] [Abstract] [Full Text] [Related]
15. Incorporating PHI in decision making: external validation of the Rotterdam risk calculators for detection of prostate cancer.
Rius Bilbao L; Aguirre Larracoechea U; Valladares Gomez C; Remmers S; Mar Medina C;
World J Urol; 2024 Mar; 42(1):141. PubMed ID: 38478041
[TBL] [Abstract] [Full Text] [Related]
16. Analysis of trend in the role of national and regional hubs in prostatectomy after prostate cancer diagnosis in the past 5 years: A nationwide population-based study.
Kim SC; Han S; Yoon JH; Park S; Moon KH; Cheon SH; Park GM; Kwon T
Investig Clin Urol; 2024 Mar; 65(2):124-131. PubMed ID: 38454821
[TBL] [Abstract] [Full Text] [Related]
17. Development and Validation of a Deep Learning Model to Reduce the Interference of Rectal Artifacts in MRI-based prostate cancer diagnosis.
Hu L; Guo X; Zhou D; Wang Z; Dai L; Li L; Li Y; Zhang T; Long H; Yu C; Shi ZW; Han C; Lu C; Zhao J; Li Y; Zha Y; Liu Z
Radiol Artif Intell; 2024 Mar; 6(2):e230362. PubMed ID: 38446042
[TBL] [Abstract] [Full Text] [Related]
18. Non-medical interventions to enhance return to work for people with cancer.
de Boer AG; Tamminga SJ; Boschman JS; Hoving JL
Cochrane Database Syst Rev; 2024 Mar; 3(3):CD007569. PubMed ID: 38441440
[TBL] [Abstract] [Full Text] [Related]
19. Performance of standard systematic biopsy versus MRI/TRUS fusion biopsy using the Navigo® system in contemporary cohort.
Nativ O; Shefler A; Bejar J; Peschansky S; Lavi A; Michael C; Nativ O
Urol Oncol; 2024 May; 42(5):159.e1-159.e7. PubMed ID: 38431487
[TBL] [Abstract] [Full Text] [Related]
20. Association between patient ethnicity and prostate cancer diagnosis following a prostate-specific antigen test: a cohort study of 730,000 men in primary care in the UK.
Down L; Barlow M; Bailey SER; Mounce LTA; Merriel SWD; Watson J; Martins T
BMC Med; 2024 Mar; 22(1):82. PubMed ID: 38424555
[TBL] [Abstract] [Full Text] [Related]
[Next]
